Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 1998

View Archived Issues

Allelix: Q3 1998 highlights

Exelon demonstrates robust effects on cognitive function in Alzheimer's disease patients

Sugen reaches milestone in collaborative agreement with Allergan

Oral aciclovir therapy reduces recurrence of herpes infection of the eye

Gene screening technology developed at Harvard Medical School licensed to Versicor

Molecular Biosystems: Q1 fiscal 1999 highlights

Single-antigen pertussis vaccine approved by FDA

Duramed receives FDA approval for hydroxyurea capsules

A significant portion of heart attack patients still do not receive proper medication

Negative interaction reported: cimetidine prolongs clarithromycin absorption

FluMist protects against influenza infection in second year of two-year study

Incel evaluated in phase II trials for the treatment of prostate cancer

Icos: Q2 1998 highlights

Roberts receives permission to launch Agrylin in Israel

Abbott discloses new antibacterial macrolides

New antiasthmatic PDE IV inhibitors revealed by Celltech

RPR reports discovery of antitumor taxoids

VivoRx discloses bifunctional paclitaxel derivatives

Searle presents new HIV protease inhibitor series

Latvian researchers discover potential new treatment for heart failure

PST-2744, an Na+/K+-ATPase inhibitor for heart failure with improved safety over digitalis

Proton pump inhibitor IY-81149 is active in models of acute and chronic gastric ulcers

Promising new antipsychotic agent in active development at Gedeon Richter

Japanese investigators study antinociceptive dynorphin analogue

European Commission approves Xenical for marketing in member countries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...